Subscribe to NRx Newsletter

Pipeline

Bringing Hope to Life through our NMDA Platform

We focus on serious, life-threatening conditions with major unmet medical needs. Our growing pipeline is powered by our proprietary, dual-targeted mechanism of action, which safely modulates the NMDA and 5HT2A receptors.

As we unlock our discoveries about the role of NMDA receptors throughout the human body, we leverage that research to bring hope to people with:

  • Depression
  • Suicidality
  • Chronic Pain
  • PTSD

Learn more about NMDA and 5HT2A Receptors >

Therapeutic Areas by Population Size in United States

PSYCHIATRY

BIPOLAR DEPRESSION & SUICIDAL IDEATION

Indication
Preclinical
Phase 1
Phase 2
Phase 3
Severe Bipolar Depression with Recently Suicidal Patients post stabilization

NRX-100™ / NRX-101™

Phase 3
FDA SPA, Breakthrough Therapy, Biomarker Letter of Support – Integrating with P2b/3
Treatment of Suicidal Treatment-Resistant Bipolar Depression

NRX-101™

Phase 3
Currently Enrolling, Phase 2b/3 – Data Readout Expected Q4 2023
Expanded Access / Safety Study

NRX-101™

Preclinical
300+ Expected by Q2 2024

CHRONIC PAIN WITH DEPRESSION

Indication
Preclinical
Phase 1
Phase 2
Phase 3
Treatment of Chronic Pain

NRX-101™

Phase 2
Awaiting results of DCS Study in Chronic Pain: NCT03535688, funded by United States Department of Defense
Depression in Patients with Chronic Pain

NRX-101™

Planning
Planning – Data Readout Expected in 2024

POST TRAUMATIC STRESS DISORDER (PTSD)

Indication
Preclinical
Phase 1
Phase 2
Phase 3
PTSD in patients with Depression & Suicidality

NRX-101™

Enrollment Pending
Commence Planning for Phase 2 in 2023

Sources:

  1. National Institute of Mental Health,  https://www.nimh.nih.gov/health/statistics/bipolar-disorder
  2. US Dept of Veteran Affairs, https://www.ptsd.va.gov/understand/common/common_adults.asp
  3. Centers for Disease Control and Prevention, https://www.cdc.gov/mmwr/volumes/72/wr/mm7215a1.htm

    Expanded Access Policy on RTT: NRX-101 is not currently available outside of clinical trials.